Fact CheckerSign in

NCT04196452Active, not recruiting

A Retrospective Observational Study on the Long-term Effects of Ipilimumab-treated Pediatric Participants in the Dutch Melanoma Treatment Registry (DMTR)

Long-term Follow-up of Ipilimumab-treated Pediatric Patients Enrolled in the Dutch Melanoma Treatment Registry (DMTR)

Source: ClinicalTrials.gov · Last updated 20 Nov 2025

Brief summary (registry, in English)

This is an observational, national, retrospective study consisting of pediatric patients with advanced (spread or unremoveable) melanoma identified in the DMTR in the Netherlands

Status (registry)
Active, not recruiting
Study type
Observational
Enrollment
10 (estimated)
First submitted
11 Dec 2019
Start date
Aug 2019
Primary completion date
Feb 2034
Lead sponsor
Bristol-Myers Squibb
NCT number
NCT04196452

What you commit to

  • Study type: Observational
  • Planned participants: 10
  • From Aug 2019 to the primary completion date, Feb 2034
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • -Participation in a clinical trial within the past 4 weeks prior to first dose with ipilimumab or concurrently

Other

  • Other inclusion/exclusion criteria apply

Who the study is looking for

  • Less than 18 years of age at first dose of monotherapy Ipilimumab used for treatment of advanced melanoma
  • Histological or cytological confirmation of advanced (unresectable or metastatic) melanoma

Criteria the registry did not label

  • For more information regarding Bristol-Myers Squibb Clinical Trials, please visit www.BMSStudyConnect.com.

Age in the registry: - to 18 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.